Current Issue-FINAL

Journal of Dermatology for Physician Assistants

The official journal of the Society of Dermatology Physician Assistants

current issue-FALL 2022

Dear Readers,

Welcome to Journal of Dermatology for Physician Assistants (JDPA) Fall 2022 issue. We are pleased to deliver you quality content on a variety of topics for which JDPA is known PLUS the SDPA Fall 2022 Digital Abstracts

See issue content and access the full digital versions today!

Submit Your Work Today

#01-Efficacy and Safety of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis in a Phase 3 Trial

SDPA Presents 20th Annual Fall Dermatology Conference–Abstracts and Posters November 16-20, 2022, Miami, FL 1. Efficacy and Safety of Roflumilast Foam 0.3% in Patients with

#03-Long-term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis in a 24-52-week, Open-label Phase 2 Trial

SDPA Presents 20th Annual Fall Dermatology Conference–Abstracts and Posters November 16-20, 2022, Miami, FL 3. Long-term Safety and Efficacy of Roflumilast Foam 0.3% in Patients

#04-Patient Perspectives on the Prevalence and Burden of Intertriginous Psoriasis: Results from a National Survey of Adults with Psoriasis in the United States

SDPA Presents 20th Annual Fall Dermatology Conference–Abstracts and Posters November 16-20, 2022, Miami, FL 4. Patient Perspectives on the Prevalence and Burden of Intertriginous Psoriasis:

#42-Non-Invasive Genomic Profiling of Pigmented Lesions – an Interim Registry Analysis

SDPA Presents 20th Annual Fall Dermatology Conference–Abstracts and Posters November 16-20, 2022, Miami, FL 42. Non-Invasive Genomic Profiling of Pigmented Lesions – an Interim Registry

#39. Deucravacitinib Long-term Efficacy with Continuous Treatment in Plaque Psoriasis: 2-Year Results from the Phase 3 POETYK PSO Study Program

SDPA Presents 20th Annual Fall Dermatology Conference–Abstracts and Posters November 16-20, 2022, Miami, FL 39. Deucravacitinib Long-term Efficacy with Continuous Treatment in Plaque Psoriasis: 2-Year

#40-Bimekizumab (BKZ) Efficacy in High-impact Areas for Patients (pts) with Moderate to Severe Plaque Psoriasis: Pooled Results through Two Years from the BE SURE and BE RADIANT Phase 3 Trials

SDPA Presents 20th Annual Fall Dermatology Conference–Abstracts and Posters November 16-20, 2022, Miami, FL 40. Bimekizumab (BKZ) Efficacy in High-impact Areas for Patients (pts) with

#41-Deucravacitinib Significantly Improves Symptoms and Signs of Psoriasis in Patients With Moderate to Severe Psoriasis: Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials

SDPA Presents 20th Annual Fall Dermatology Conference–Abstracts and Posters November 16-20, 2022, Miami, FL 41. Deucravacitinib Significantly Improves Symptoms and Signs of Psoriasis in Patients

Journal of Dermatology for Physician Assistants

current issue-FALL 2022

Submit Your Work Today

Table of Contents

#01-Efficacy and Safety of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis in a Phase 3 Trial

#03-Long-term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis in a 24-52-week, Open-label Phase 2 Trial

#04-Patient Perspectives on the Prevalence and Burden of Intertriginous Psoriasis: Results from a National Survey of Adults with Psoriasis in the United States

#42-Non-Invasive Genomic Profiling of Pigmented Lesions – an Interim Registry Analysis

#39. Deucravacitinib Long-term Efficacy with Continuous Treatment in Plaque Psoriasis: 2-Year Results from the Phase 3 POETYK PSO Study Program

#40-Bimekizumab (BKZ) Efficacy in High-impact Areas for Patients (pts) with Moderate to Severe Plaque Psoriasis: Pooled Results through Two Years from the BE SURE and BE RADIANT Phase 3 Trials

#41-Deucravacitinib Significantly Improves Symptoms and Signs of Psoriasis in Patients With Moderate to Severe Psoriasis: Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials

Featured

Teamwork is the Only Way

Bullous Pemphigoid: Diagnosis, Treatment, and Management

Atopic Eruption of Pregnancy: A Case Report and Brief Topic Overview

On Individualized Eczema Care: No Two Patients Are Alike

The Saga of the Modifier 25

Listening To Patients: Physician Extenders

How the SDPA & PA Community Demonstrated Resilience, Unity, & Progress During the Most Challenging Year in Recent Healthcare History

Racial Disparity in Melanoma Survival Among Non-Hispanic Black Patients

Spots on Tots: A Case Study of a Widespread Asymptomatic Rash in a Pediatric Patient

From The Patient’s Perspective: Living with Cutaneous Lymphoma

Congenital Cartilaginous Rest of the Neck: A Case Report and Topic Overview

Adjusting to the New 2021 Evaluation & Management Documentation Guidelines

A YEAR LATER. Lessons Learned from Practicing Dermatology in a Pandemic

Listening To Patients: Getting the Right Drug

How 2020 Taught Us to See Opportunity through Obstacle

Journal of Dermatology for Physician Assistants